BioNTech's RNA cancer therapy trial halted early
NCT ID NCT05262530
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental RNA-based therapy called BNT142 in people with advanced solid tumors that have a specific protein called CLDN6. The goal was to see if it was safe and could shrink tumors. However, the trial was terminated early, so we don't have clear answers about whether it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BNT142 (an experimental RNA-based therapy)
- What this could lead to
- If it had worked, this could have pointed toward a new treatment option for certain advanced solid tumors that express the CLDN6 protein.
- What could go wrong
- The trial was terminated early, so we don't know if BNT142 is safe or effective. It was a very early study (Phase 1/2a) with only 73 participants, so even positive results would need much more testing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cambridge University Hospitals NHS Foundation Trust
Cambridge, CB2 0QQ, United Kingdom
-
Churchill Hospital - Oxford University Hospitals NHS Foundation Trust
Oxford, OX3 7LE, United Kingdom
-
Duke University Medical Center
Durham, North Carolina, 27705, United States
-
HM Nou Delfos General Hospital
Barcelona, 08023, Spain
-
Hammersmith Hospital, Imperial College School Of Medicine - Imperial College Healthcare NHS Trust
London, W12 0HS, United Kingdom
-
Hospital Universitario 12 de Octubre - Centro de Actividades Ambulatorias
Madrid, 28041, Spain
-
Hospital Universitario Vall D'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario Virgen de la Victoria Campus Universitario de Teatinos
Málaga, 29010, Spain
-
MD Anderson Cancer Center
Madrid, 28033, Spain
-
NEXT Virginia
Fairfax, Virginia, 22031, United States
-
National University Cancer Institute - National University Hospital
Singapore, 119074, Singapore
-
START Madrid CIOCC Hospital Universitario HM Sanchinarro
Madrid, 28050, Spain
-
START Madrid-FJD Hospital Universitario Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
South Texas Accelerated Research Therapeutics (START) - San Antonio
San Antonio, Texas, 78229, United States
-
The Clatterbridge Cancer Centre NHS Foundation Trust
Liverpool, L7 8YA, United Kingdom
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Maryland Medical Center
Baltimore, Maryland, 21201, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a Tumor's DNA guide better cancer care for kids?
- What raises endometrial cancer risk in black women? a study digs in
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?